HPV Wart Treatment Guidelines

Introduction to HPV Wart Treatment

The primary goal of HPV wart treatment is removal of symptomatic visible warts, not HPV eradication, as no currently available treatment eliminates the virus from surrounding tissue or affects the natural history of HPV infection 1, 2, 3
Treatment may or may not decrease infectivity, and there is no evidence that treating visible warts affects cervical cancer development 1, 2
Untreated warts spontaneously resolve in 20-30% of patients within 3 months, remain unchanged, or increase in size/number 1, 3

The Centers for Disease Control and Prevention recommends cryotherapy or patient-applied podofilox/imiquimod as first-line options, recognizing that all treatments remove visible warts but do not eradicate HPV, and recurrence occurs in approximately 25-30% of cases regardless of modality 1, 2
Cryotherapy with liquid nitrogen is a preferred first-line provider-administered treatment with efficacy of 63-88% and recurrence rates of 21-39% 4
Podofilox 0.5% solution or gel should be applied twice daily for 3 consecutive days, followed by 4 days of no therapy; repeat cycle up to 4 times, and is contraindicated in pregnancy 1, 2, 4
Imiquimod cream is available as patient-applied immunomodulator therapy, works better on moist surfaces and intertriginous areas than dry surfaces, and is contraindicated in pregnancy 1, 2, 4
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80-90% can be used, especially in pregnancy, and should be applied only to warts, powder with talc or sodium bicarbonate to remove unreacted acid, and repeat weekly if necessary 1, 2, 4

Change treatment modality if the patient has not improved substantially after 3 provider-administered treatments or if warts have not completely cleared after 6 treatments 1, 2
Small warts present less than 1 year respond better to treatment 3
Warts on moist/intertriginous areas respond better to topical treatments 1, 2
Factors influencing treatment choice include wart size, number, and anatomic location, wart morphology, patient preference and ability to attend office visits, cost, convenience, and provider experience, and pregnancy status 1, 2, 4, 5

In pregnancy, use only cryotherapy and TCA as safer alternatives, and avoid podofilox, podophyllin, and imiquimod 4
Inform patients that HPV types 6 and 11 cause over 90% of genital warts and are low-risk types that do not cause cancer, and that recurrence is common (approximately 30%) regardless of treatment method due to reactivation of subclinical infection, not reinfection by a partner 3, 4, 6
The American College of Obstetricians and Gynecologists recommends that patients be informed about the risks and benefits of treatment, including the potential for recurrence and the importance of follow-up care 4